Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center

Journal of Burn Care and Research

Volumn 28, Issue 6, 2007, Pages 865-870

  Dore, Jennifer ^a   Salisbury, Roger E ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Westchester Burn Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; ASPARAGINASE; AZITHROMYCIN; CEFIXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; COTRIMOXAZOLE; IBUPROFEN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN;

ADOLESCENT; BURN; BURN UNIT; CHI SQUARE TEST; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHEMA MULTIFORME; EXFOLIATING SKIN DISEASE; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOPLASMA; PEDIATRICS; PNEUMONIA; SEPSIS; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TERTIARY HEALTH CARE; TOXIC EPIDERMAL NECROLYSIS; UROGENITAL TRACT DISEASE;

ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; AZITHROMYCIN; BURN UNITS; CEFIXIME; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; EYE DISEASES; FEMALE; HUMANS; IBUPROFEN; INFANT; MALE; MULTIVARIATE ANALYSIS; PHENYTOIN; PNEUMONIA; SEPSIS; STEVENS-JOHNSON SYNDROME; URETHRAL STRICTURE;

EID: 36048950527     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318159a3c7     Document Type: Conference Paper

References (23)

1. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Steven's Johnson syndrome: does early withdrawal of causative drugs decrease risk of death? Arch Dermatol 2000;136:323-7.
2. Available from http://www.msnbc.msn.com/id/6986891;Internet.
3. Forman R, Koren G, Shear N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years experience. Drug Saf 2002;25:965-72.
4. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with high dose immunoglobulins: our experience. Dermatology 2001;203:45-9.
5. Brown K, Silver G, Halerz M, Walasek P, Sandroni A, Gamelli R. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8.
6. Roger S, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.
7. Bachot N, Revuz J, Roujeau J. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003;139:33-6.
8. Patterson R, Dykewicz MS, Gonzales A, et al. Erythema multiforme and Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest 1990;98:331-6.
9. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival in patients with TEN without corticosteroids. Ann Surg 1986;204:503-12.
10. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005;136:205-16.
11. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli R. Long-term follow up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26-33.
12. Yetiv J, Bianchine J, Owen J. Etiologic factors in Stevens-Johnson syndrome. South Med J 1980;7:599-602.
13. Guibal F, Bastuji-Garin S, Chhosidow O, Saiag P, Revuz J, Roujeau JC. Charactersitics of toxic epidermal necrolysis in patients undergoing long-term gluccocorticoid therapy. Arch Dermatol 1995;131:669-72.
14. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996;98:1112-15.
15. Stern RS. Improving the outcome of patients with toxic epidermal necrolysis. Arch Dermatol 2000;136:410-11.
16. Prendiville J, Herbert A, Greenwald M, Esterly N. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-7.
17. Roujeau JC, Kelly J, Naldi L, et al. Medication use and the risk of toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
18. Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA. Serious skin reactions and selective COX-2 inhibitors; a case series from prescription-event monitoring in England. Drug Saf 2006;29:687-96.
19. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade with human intravenous immunoglobulin. Science 1998;282:490-3.
20. Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55:27-33.
21. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxgenase-independent actions of cycloxygenase inhibitors. FASEB J 2001;15:2057-72.
22. Taghian M, Tran A, Bresson-Hadani S, Menget A, Felix S, Jacquemin E. Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr 2004;145:273-6.
23. Srivastava M, Perez-Atayde A, Jonas M. Drug associated acute-onset vanishing bile duct and Stevens-Johnson syndrome in a child. Gastroenterology 1998;115:743-6.